Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Analysis Of Recent Drug Reviews Illuminates Path For Future NDAs

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Every month, Pharmaceutical Approvals Monthly dissects a new drug review by FDA. Using FDA’s own review documents, including the discipline reviews, decision memos, meeting minutes, emails, and other documents, we strive to illuminate the agency decision-making process.

You may also be interested in...



Drug Review Documents Hint At Impact Of Broad Changes At FDA

The last year has been a year of dramatic changes at FDA, as the agency implements the sweeping new authorities of the FDA Amendments Act. As industry tries to stay abreast of the new world of FDA, taking a closer look at how some of those changes played out in individual case studies – through the lens of Pharmaceutical Approvals Monthly’s drug review profiles – can yield some valuable lessons for companies preparing for the gauntlet of an FDA review.

FDA, Industry Unveil Mechanistic Trial Simulation Models

FDA partnered with industry to create four trial simulation models for Parkinson's disease, diabetes, depression and measuring cancer progression, which were unveiled at the Jan. 24-25 Drug Industry Association meeting on "Sharing Knowledge To Improve Clinical Drug Development and Regulatory Decisions.

Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Topics

UsernamePublicRestriction

Register

PS003756

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel